237 related articles for article (PubMed ID: 32965568)
1. Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.
Bunevicius A; Miller J; Parsons M
Curr Oncol Rep; 2020 Sep; 22(12):120. PubMed ID: 32965568
[TBL] [Abstract][Full Text] [Related]
2. Understanding cognitive functioning in glioma patients: The relevance of IDH-mutation status and functional connectivity.
Derks J; Kulik S; Wesseling P; Numan T; Hillebrand A; van Dellen E; de Witt Hamer PC; Geurts JJG; Reijneveld JC; Stam CJ; Klein M; Douw L
Brain Behav; 2019 Apr; 9(4):e01204. PubMed ID: 30809977
[TBL] [Abstract][Full Text] [Related]
3. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
5. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
6. Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.
Parsons MW; Sabsevitz DS
J Neurooncol; 2023 May; 162(3):525-533. PubMed ID: 36940053
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.
Low SK; Anjum Z; Mahmoud A; Joshi U; Kouides P
Thromb Res; 2022 Nov; 219():14-21. PubMed ID: 36088710
[TBL] [Abstract][Full Text] [Related]
8. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
11. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
12. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
[TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
14. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
[TBL] [Abstract][Full Text] [Related]
15. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
Unruh D; Zewde M; Buss A; Drumm MR; Tran AN; Scholtens DM; Horbinski C
Sci Rep; 2019 Jun; 9(1):8946. PubMed ID: 31222125
[TBL] [Abstract][Full Text] [Related]
16. IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.
Di Carlo DT; Duffau H; Cagnazzo F; Benedetto N; Morganti R; Perrini P
Neurosurg Rev; 2020 Apr; 43(2):383-395. PubMed ID: 29943141
[TBL] [Abstract][Full Text] [Related]
17. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
19. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
20. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
Sears TK; Woolard KD
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
